| Literature DB >> 35919794 |
Zelal Kharaba1, Sedq A Moutraji2, Rama A Al Khawaldeh3, Yassen Alfoteih4, Ahmad Z Al Meslamani5.
Abstract
Objectives: The study aimed to investigate the impact of Coronavirus disease (COVID-19) on the roles of hospital and community pharmacists in the United Arab Emirates (UAE) and to assess how COVID-19 has affected their roles concerning medication dispensing and review, patient education, and telepharmacy services.Entities:
Keywords: COVID-19; Information technology tools; Medication dispensing; Medication review; Patient education; Pharmaceutical Care; Telepharmacy
Year: 2022 PMID: 35919794 PMCID: PMC9296094 DOI: 10.18549/PharmPract.2022.2.2656
Source DB: PubMed Journal: Pharm Pract (Granada) ISSN: 1885-642X
Operational definitions of the study17,18
| Term | Definition |
|---|---|
| Antibiotics | Effective antibacterial agents required for preventive and curative measures, protecting patients from potentially fatal diseases and infections. |
| Medication Review | Medication review is a structured evaluation of a patient’s medicines with the aim of optimizing medicines use and improving health outcomes. |
| Medication Related Problems (MRPs) | A drug therapy problem is any undesirable event experienced by a patient that involves, or is suspected to involve, drug therapy, and that interferes with achieving the desired goals of therapy and requires professional judgment to resolve. |
| OTC (over the counter) medications | A medicine or device that can be bought without a doctor’s order or prescription. |
| Quarantine | Restriction of the activities and movement of well persons or animals who may have been exposed to a case of communicable disease. |
| Self-Isolation | A method used by an individual to be kept apart in seclusion from others for a period of time in an attempt to minimize the risk of transmission of an infectious disease. |
| Symptoms | * Subjective evidence of disease perceived by the patient. |
| Telepharmacy | The use of electronic information and communication technologies to provide and support health care when distance separates the participants. |
Sociodemographic information of pharmacists included in the study N = 428)
| Parameters | Total, n (%) | Practice teleconsultation, n (%) 330 (77.1%) | Do not practice teleconsultation, n (%) 98 (22.9%) | P value | |
|---|---|---|---|---|---|
|
| Female | 256 (59.8) | 195 (76.2) | 61 (23.8) | 0.576 |
| Male | 172 (40.2) | 135 (78.5) | 37 (21.5) | ||
|
| 22-24years | 69 (16.1) | 59 (85.5) | 10 (14.5) | 0.096 |
| 25-45years | 348 (81.3) | 263 (75.6) | 85 (24.4) | ||
| > 45years | 11 (2.6) | 8 (72.7) | 3 (27.3) | ||
|
| <2 | 66 (15.4) | 50 (75.8) | 16 (24.2) | 0.236 |
| 2-5 | 168 (39.3) | 135 (80.4) | 33 (19.6) | ||
| 6-10 | 129 (30.1) | 97 (75.2) | 32 (24.8) | ||
| >10 | 65 (15.2) | 51 (78.4) | 14 (21.6 | ||
|
| Bachelor of science | 359 (83.9) | 286 (79.7) | 73 (20.3) |
|
| Doctor of Pharmacy (MSc) | 52 (12.1) | 33 (63.5) | 19 (36.5) | ||
| Diploma | 16 (3.7) | 10 (62.5) | 6 (37.5) | ||
| Doctorate | 1 (0.2) | 1 (100.0) | 0 (0.0) | ||
|
| Capital region (Abu Dhabi) | 235 (54.9) | 183 (77.9) | 52 (22.1) | 0.498 |
| Northern Region (Ras al-Khaimah, Sharjah, Ajman, Fujeirah and Umm al-Quwain) | 142 (33.2) | 110 (77.5) | 32 (22.5) | ||
| Central Region (Dubai) | 51 (11.9) | 36 (70.6) | 15 (29.4) | ||
|
| Community | 339 (79.2) | 264 (77.9) | 75 (22.1) | 0.457 |
| Hospital | 89 (20.2) | 66 (74.2) | 23 (25.8) | ||
Data are presented as numbers (n) and percentages (%). Bold p values are significant results; p< 0.05. Pearson’s chi-squared test was used to measure differences in demographic information across pharmacists who practiced teleconsultation and those who did not.
Assessment of changes to medication dispensing and patient safety practices after COVID-19 (N = 428)
| Parameters | Altered at least a prescription or a dosage regimen for a COVID-19 patient | Filled prescriptions remotely | ||||
|---|---|---|---|---|---|---|
| Yes, n (%) Total = | No, n (%) Total= | P value | Yes, n (%) Total = | No, n (%) Total = | P value | |
|
| ||||||
| The rate of medication dispensing after COVID-19. | 0.084 | 0.127 | ||||
| Increased | 132 (55.7%) | 105 (44.3%) | 152 (64.1%) | 85 (35.9%) | ||
| Decreased | 65 (45.8%) | 77 (54.2%) | 80 (56.3%) | 62 (43.7%) | ||
| The rate of OTC medicines dispensing after COVID-19. |
| 0.076 | ||||
| Increased | 174 (55.4%) | 140 (44.6%) | 195 (62.1%) | 119 (37.9%) | ||
| Decreased | 27 (35.5%) | 49 (64.5%) | 37 (48.7%) | 39 (51.3%) | ||
| The rate of vitamins dispensing after COVID-19. | 0.073 | 0.893 | ||||
| Increased | 208 (50.6%) | 203 (49.4%) | 246 (59.9%) | 165 (40.1%) | ||
| Decreased | 5 (100%) | 0 (0%) | 3 (60%) | 2 (40%) | ||
| The rate of antibiotics dispensing after COVID-19. |
| 0.141 | ||||
| Increased | 131 (62.4%) | 79 (37.6%) | 136 (64.8%) | 74 (35.2%) | ||
| Decreased | 38 (35.8%) | 68 (64.2%) | 60 (56.6%) | 46 (43.4%) | ||
|
| ||||||
| Engagement in patient education after COVID-19. |
| 0.153 | ||||
| Increased | 195 (51.3%) | 185 (48.7%) | 219 (62%) | 134 (38%) | ||
| Decreased | 7 (25.9%) | 20 (74.1%) | 15 (55.6%) | 12 (44.4%) | ||
| Engagement in medication review after COVID-19. | 0.072 | 0.723 | ||||
| Increased | 178 (54.3%) | 150 (45.7%) | 200 (61%) | 128 (39%) | ||
| Decreased | 9 (37.5%) | 15 (62.5%) | 14 (58.3%) | 10 (41.7%) | ||
| Pharmaceutical intervention on prescriptions after COVID-19. | 0.563 |
| ||||
| Increased | 157 (63.6%) | 90 (36.4%) | 167 (67.6%) | 80 (32.4%) | ||
| Decreased | 11 (24.4%) | 34 (75.6%) | 17 (37.8%) | 28 (62.2%) | ||
| The rate of physicians’ acceptance of pharmacists’ interventions after COVID-19. |
|
| ||||
| Increased | 115 (64.2%) | 64 (35.8%) | 122 (68.2%) | 57 (31.8%) | ||
| Decreased | 19 (42.2%) | 26 (57.8%) | 20 (28.6%) | 50 (71.4%) | ||
| The rate of MRPs after COVID-19. |
| 0.203 | ||||
| Increased | 102 (64.2%) | 57 (35.8%) | 102 (64.2%) | 57 (35.8%) | ||
| Decreased | 12 (27.3%) | 32 (72.7%) | 21 (41.2%) | 30 (58.8%) | ||
| Patient access to pharmaceutical care after COVID-19? | 0.138 |
| ||||
| Increased | 178 (53.5%) | 155 (46.5%) | 209 (62.8%) | 124 (37.2%) | ||
| Decreased | 27 (43.5%) | 35 (56.5%) | 36 (58.1%) | 26 (41.9%) | ||
Those who answered same as before were excluded from this analysis. Bold p values indicate significant results p< 0.05. Data are presented as numbers (n) and percentages (%).
Figure 1Counseling areas that pharmacists have been engaged in after COVID-19.
Figure 2The impact of years of experience on pharmaceutical care changes after COVID-19 in UAE. Errors bars reflect 95% CI.